Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.
The low titer and incidence of autologous antibody to melanoma has hampered its evaluation. Through acid dissociation and ultrafiltration of serum, we have been able to augment the autologous immune response in 9 of 10 patients studied. This result suggests that autologous antibody is present in most patients with melanoma, but is obscured by circulating antigen and the formation of immune complexes. Because native antibody and antibody derived from circulating immune complexes are produced by the host against physiologically relevant antigens, correlations can be made to clinical course. Serological studies of three patients with melanoma were performed with serum samples obtained over many months; these studies demonstrated correlations with tumor progression and clinical course. Serial serologic studies may yet provide one of the better ways to evaluate these relationships. They have the advantage of detecting transient events that may occur with the inception of metastatic disease or autoimmune phenomena, and of avoiding the difficulties encountered in comparing antibody responses between different individuals.
D000818:Animals; D000917:Antibody Formation; D000936:Antigen-Antibody Complex / Q000032:analysis*; D002460:Cell Line; D003166:Complement Activating Enzymes / Q000378:metabolism; D015922:Complement C1q; D005260:Female; D006801:Humans; D008545:Melanoma / Q000276:immunology*; D011247:Pregnancy; D011379:Prognosis; D012756:Sheep; D013205:Staphylococcal Protein A; D014462:Ultrafiltration
D000936:Antigen-Antibody Complex; D013205:Staphylococcal Protein A; D015922:Complement C1q; D003166:Complement Activating Enzymes